Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Nat-Donepezil (02439557), Nat-Donepezil (02439565). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.
DONEPEZIL HCL
All strengths: Limited Use — Reason for Use code 347, 348 required; same patient cost rules
Shared coverage and patient cost rules
StatusLimited Use — Reason for Use code 347, 348 required
Patient paysPatient pays: program not supplied; amount cannot be determined.
Other products in the same Health Canada class (N06DA) — coverage varies; not interchangeable
- Galantamine (Reminyl ER): limited Use 347, 348, Not a benefit
- Rivastigmine (Exelon): limited Use 347, 348, Not a benefit
AG-Donepezil · DIN 02432684 · 5mg · tablet
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
AG-Donepezil · DIN 02432684
Manufacturer: Angita Pharma Inc.; listing date 2021-09-30
Health Canada: Marketed since 2021-05-10 · brand AG-DONEPEZIL · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE 5 MG · company Angita pharma inc. · schedule Prescription
AG-Donepezil: Formulary list price $0.4586/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4586 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91711 · Verify on the e-Formulary ↗ (DIN 02432684)
Source record
DIN 02432684: AG-Donepezil
Raw flags: sec12=Y, sec3=Y
Item: 120400017; group id 193; item number 0354; lccId 00026; manufacturer id ANG
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4586; ministry $0.4586
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02432684
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91711
Interchangeable products
Ach-Donepezil · DIN 02402645 · $0.4586
Apo-Donepezil · DIN 02362260 · $0.4586
Aricept · DIN 02232043 · $0.4586
Auro-Donepezil · DIN 02400561 · $0.4586
Bio-Donepezil · DIN 02412853 · $0.4586
Co Donepezil · DIN 02397595 · $0.4586
Donepezil · DIN 02420597 · $0.4586
Donepezil · DIN 02426846 · $0.4586
Donepezil · DIN 02475278 · $0.4586
Jamp-Donepezil · DIN 02404419 · $0.4586
Jamp-Donepezil Tablets · DIN 02416948 · $0.4586
M-Donepezil · DIN 02467453 · $0.4586
Mar-Donepezil · DIN 02402092 · $0.4586
Mint-Donepezil · DIN 02408600 · $0.4586
NRA-Donepezil · DIN 02535386 · $0.4586
PMS-Donepezil · DIN 02322331 · $0.4586
Ran-Donepezil · DIN 02381508 · $0.4586
Sandoz Donepezil · DIN 02328666 · $0.4586
Septa-Donepezil · DIN 02428482 · $0.4586
Teva-Donepezil · DIN 02340607 · $0.4586
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02432684
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ach-Donepezil · DIN 02402645 · 5mg · tablet
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ach-Donepezil · DIN 02402645
Manufacturer: Accord Healthcare Inc.; listing date 2014-05-29
Health Canada: Marketed since 2022-12-12 · brand ACH-DONEPEZIL · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE 5 MG · company Accord healthcare inc · schedule Prescription
Ach-Donepezil: Formulary list price $0.4586/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4586 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88749 · Verify on the e-Formulary ↗ (DIN 02402645)
Source record
DIN 02402645: Ach-Donepezil
Raw flags: sec12=Y, sec3=Y
Item: 120400017; group id 193; item number 0354; lccId 00026; manufacturer id ACH
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4586; ministry $0.4586
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02402645
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88749
Interchangeable products
AG-Donepezil · DIN 02432684 · $0.4586
Apo-Donepezil · DIN 02362260 · $0.4586
Aricept · DIN 02232043 · $0.4586
Auro-Donepezil · DIN 02400561 · $0.4586
Bio-Donepezil · DIN 02412853 · $0.4586
Co Donepezil · DIN 02397595 · $0.4586
Donepezil · DIN 02420597 · $0.4586
Donepezil · DIN 02426846 · $0.4586
Donepezil · DIN 02475278 · $0.4586
Jamp-Donepezil · DIN 02404419 · $0.4586
Jamp-Donepezil Tablets · DIN 02416948 · $0.4586
M-Donepezil · DIN 02467453 · $0.4586
Mar-Donepezil · DIN 02402092 · $0.4586
Mint-Donepezil · DIN 02408600 · $0.4586
NRA-Donepezil · DIN 02535386 · $0.4586
PMS-Donepezil · DIN 02322331 · $0.4586
Ran-Donepezil · DIN 02381508 · $0.4586
Sandoz Donepezil · DIN 02328666 · $0.4586
Septa-Donepezil · DIN 02428482 · $0.4586
Teva-Donepezil · DIN 02340607 · $0.4586
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02402645
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Donepezil · DIN 02362260 · 5mg · tablet
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Donepezil · DIN 02362260
Manufacturer: Apotex Inc.; listing date 2014-02-27
Health Canada: Marketed since 2013-12-27 · brand APO-DONEPEZIL · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE (DONEPEZIL HYDROCHLORIDE MONOHYDRATE) 5 MG · company Apotex inc · schedule Prescription
Apo-Donepezil: Formulary list price $0.4586/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4586 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84728 · Verify on the e-Formulary ↗ (DIN 02362260)
Source record
DIN 02362260: Apo-Donepezil
Raw flags: sec12=Y, sec3=Y
Item: 120400017; group id 193; item number 0354; lccId 00026; manufacturer id APX
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4586; ministry $0.4586
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02362260
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84728
Interchangeable products
AG-Donepezil · DIN 02432684 · $0.4586
Ach-Donepezil · DIN 02402645 · $0.4586
Aricept · DIN 02232043 · $0.4586
Auro-Donepezil · DIN 02400561 · $0.4586
Bio-Donepezil · DIN 02412853 · $0.4586
Co Donepezil · DIN 02397595 · $0.4586
Donepezil · DIN 02420597 · $0.4586
Donepezil · DIN 02426846 · $0.4586
Donepezil · DIN 02475278 · $0.4586
Jamp-Donepezil · DIN 02404419 · $0.4586
Jamp-Donepezil Tablets · DIN 02416948 · $0.4586
M-Donepezil · DIN 02467453 · $0.4586
Mar-Donepezil · DIN 02402092 · $0.4586
Mint-Donepezil · DIN 02408600 · $0.4586
NRA-Donepezil · DIN 02535386 · $0.4586
PMS-Donepezil · DIN 02322331 · $0.4586
Ran-Donepezil · DIN 02381508 · $0.4586
Sandoz Donepezil · DIN 02328666 · $0.4586
Septa-Donepezil · DIN 02428482 · $0.4586
Teva-Donepezil · DIN 02340607 · $0.4586
Shortage status: active shortage (reported 2025-11-18, last updated 2025-11-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02362260
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Aricept · DIN 02232043 · 5mg · tablet
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Savings card: RxHelp ONE lists Aricept (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Aricept · DIN 02232043
Manufacturer: Pfizer Canada Inc.; listing date 1999-06-01
Health Canada: Marketed since 1997-08-20 · brand ARICEPT · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE 5 MG · company Pfizer canada ulc · schedule Prescription
Ministry pays: $0.4586 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=51491 · Verify on the e-Formulary ↗ (DIN 02232043)
Source record
DIN 02232043: Aricept
Raw flags: sec12=Y, sec3=Y
Item: 120400017; group id 193; item number 0354; lccId 00026; manufacturer id PFI
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $5.1856; ministry $0.4586
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02232043
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=51491
Interchangeable products
AG-Donepezil · DIN 02432684 · $0.4586
Ach-Donepezil · DIN 02402645 · $0.4586
Apo-Donepezil · DIN 02362260 · $0.4586
Auro-Donepezil · DIN 02400561 · $0.4586
Bio-Donepezil · DIN 02412853 · $0.4586
Co Donepezil · DIN 02397595 · $0.4586
Donepezil · DIN 02420597 · $0.4586
Donepezil · DIN 02426846 · $0.4586
Donepezil · DIN 02475278 · $0.4586
Jamp-Donepezil · DIN 02404419 · $0.4586
Jamp-Donepezil Tablets · DIN 02416948 · $0.4586
M-Donepezil · DIN 02467453 · $0.4586
Mar-Donepezil · DIN 02402092 · $0.4586
Mint-Donepezil · DIN 02408600 · $0.4586
NRA-Donepezil · DIN 02535386 · $0.4586
PMS-Donepezil · DIN 02322331 · $0.4586
Ran-Donepezil · DIN 02381508 · $0.4586
Sandoz Donepezil · DIN 02328666 · $0.4586
Septa-Donepezil · DIN 02428482 · $0.4586
Teva-Donepezil · DIN 02340607 · $0.4586
Shortage status: active shortage (reported 2026-04-21, estimated to end 2026-10-23, last updated 2026-07-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02232043
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Donepezil · DIN 02400561 · 5mg · tablet
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Donepezil · DIN 02400561
Manufacturer: Auro Pharma Inc.; listing date 2014-03-27
Health Canada: Marketed since 2013-12-27 · brand AURO-DONEPEZIL · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE 5 MG · company Auro pharma inc · schedule Prescription
Auro-Donepezil: Formulary list price $0.4586/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4586 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88536 · Verify on the e-Formulary ↗ (DIN 02400561)
Source record
DIN 02400561: Auro-Donepezil
Raw flags: sec12=Y, sec3=Y
Item: 120400017; group id 193; item number 0354; lccId 00026; manufacturer id AUR
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4586; ministry $0.4586
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02400561
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88536
Interchangeable products
AG-Donepezil · DIN 02432684 · $0.4586
Ach-Donepezil · DIN 02402645 · $0.4586
Apo-Donepezil · DIN 02362260 · $0.4586
Aricept · DIN 02232043 · $0.4586
Bio-Donepezil · DIN 02412853 · $0.4586
Co Donepezil · DIN 02397595 · $0.4586
Donepezil · DIN 02420597 · $0.4586
Donepezil · DIN 02426846 · $0.4586
Donepezil · DIN 02475278 · $0.4586
Jamp-Donepezil · DIN 02404419 · $0.4586
Jamp-Donepezil Tablets · DIN 02416948 · $0.4586
M-Donepezil · DIN 02467453 · $0.4586
Mar-Donepezil · DIN 02402092 · $0.4586
Mint-Donepezil · DIN 02408600 · $0.4586
NRA-Donepezil · DIN 02535386 · $0.4586
PMS-Donepezil · DIN 02322331 · $0.4586
Ran-Donepezil · DIN 02381508 · $0.4586
Sandoz Donepezil · DIN 02328666 · $0.4586
Septa-Donepezil · DIN 02428482 · $0.4586
Teva-Donepezil · DIN 02340607 · $0.4586
Shortage status: resolved shortage (ended 2024-05-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02400561
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Bio-Donepezil · DIN 02412853 · 5mg · tablet
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Bio-Donepezil · DIN 02412853
Manufacturer: Biomed Pharma; listing date 2016-04-29
Health Canada: Marketed since 2013-12-27 · brand BIO-DONEPEZIL · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE 5 MG · company Biomed pharma · schedule Prescription
Bio-Donepezil: Formulary list price $0.4586/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4586 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89756 · Verify on the e-Formulary ↗ (DIN 02412853)
Source record
DIN 02412853: Bio-Donepezil
Raw flags: sec12=Y, sec3=Y
Item: 120400017; group id 193; item number 0354; lccId 00026; manufacturer id BMP
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4586; ministry $0.4586
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02412853
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89756
Interchangeable products
AG-Donepezil · DIN 02432684 · $0.4586
Ach-Donepezil · DIN 02402645 · $0.4586
Apo-Donepezil · DIN 02362260 · $0.4586
Aricept · DIN 02232043 · $0.4586
Auro-Donepezil · DIN 02400561 · $0.4586
Co Donepezil · DIN 02397595 · $0.4586
Donepezil · DIN 02420597 · $0.4586
Donepezil · DIN 02426846 · $0.4586
Donepezil · DIN 02475278 · $0.4586
Jamp-Donepezil · DIN 02404419 · $0.4586
Jamp-Donepezil Tablets · DIN 02416948 · $0.4586
M-Donepezil · DIN 02467453 · $0.4586
Mar-Donepezil · DIN 02402092 · $0.4586
Mint-Donepezil · DIN 02408600 · $0.4586
NRA-Donepezil · DIN 02535386 · $0.4586
PMS-Donepezil · DIN 02322331 · $0.4586
Ran-Donepezil · DIN 02381508 · $0.4586
Sandoz Donepezil · DIN 02328666 · $0.4586
Septa-Donepezil · DIN 02428482 · $0.4586
Teva-Donepezil · DIN 02340607 · $0.4586
Shortage status: resolved shortage (ended 2021-10-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02412853
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Donepezil · DIN 02420597 · 5mg · tablet
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Donepezil · DIN 02420597
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2022-07-29
Health Canada: Marketed since 2025-07-08 · brand DONEPEZIL · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE 5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Donepezil: Formulary list price $0.4586/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4586 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90516 · Verify on the e-Formulary ↗ (DIN 02420597)
Source record
DIN 02420597: Donepezil
Raw flags: sec12=Y, sec3=Y
Item: 120400017; group id 193; item number 0354; lccId 00026; manufacturer id SIV
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4586; ministry $0.4586
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02420597
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90516
Interchangeable products
AG-Donepezil · DIN 02432684 · $0.4586
Ach-Donepezil · DIN 02402645 · $0.4586
Apo-Donepezil · DIN 02362260 · $0.4586
Aricept · DIN 02232043 · $0.4586
Auro-Donepezil · DIN 02400561 · $0.4586
Bio-Donepezil · DIN 02412853 · $0.4586
Co Donepezil · DIN 02397595 · $0.4586
Donepezil · DIN 02426846 · $0.4586
Donepezil · DIN 02475278 · $0.4586
Jamp-Donepezil · DIN 02404419 · $0.4586
Jamp-Donepezil Tablets · DIN 02416948 · $0.4586
M-Donepezil · DIN 02467453 · $0.4586
Mar-Donepezil · DIN 02402092 · $0.4586
Mint-Donepezil · DIN 02408600 · $0.4586
NRA-Donepezil · DIN 02535386 · $0.4586
PMS-Donepezil · DIN 02322331 · $0.4586
Ran-Donepezil · DIN 02381508 · $0.4586
Sandoz Donepezil · DIN 02328666 · $0.4586
Septa-Donepezil · DIN 02428482 · $0.4586
Teva-Donepezil · DIN 02340607 · $0.4586
Shortage status: resolved shortage (ended 2025-07-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02420597
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Donepezil · DIN 02426846 · 5mg · tablet
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Donepezil · DIN 02426846
Manufacturer: Sanis Health Inc.; listing date 2018-05-31
Health Canada: Marketed since 2025-07-31 · brand DONEPEZIL · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE 5 MG · company Sanis health inc · schedule Prescription
Donepezil: Formulary list price $0.4586/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4586 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91139 · Verify on the e-Formulary ↗ (DIN 02426846)
Source record
DIN 02426846: Donepezil
Raw flags: sec12=Y, sec3=Y
Item: 120400017; group id 193; item number 0354; lccId 00026; manufacturer id SAI
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4586; ministry $0.4586
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02426846
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91139
Interchangeable products
AG-Donepezil · DIN 02432684 · $0.4586
Ach-Donepezil · DIN 02402645 · $0.4586
Apo-Donepezil · DIN 02362260 · $0.4586
Aricept · DIN 02232043 · $0.4586
Auro-Donepezil · DIN 02400561 · $0.4586
Bio-Donepezil · DIN 02412853 · $0.4586
Co Donepezil · DIN 02397595 · $0.4586
Donepezil · DIN 02420597 · $0.4586
Donepezil · DIN 02475278 · $0.4586
Jamp-Donepezil · DIN 02404419 · $0.4586
Jamp-Donepezil Tablets · DIN 02416948 · $0.4586
M-Donepezil · DIN 02467453 · $0.4586
Mar-Donepezil · DIN 02402092 · $0.4586
Mint-Donepezil · DIN 02408600 · $0.4586
NRA-Donepezil · DIN 02535386 · $0.4586
PMS-Donepezil · DIN 02322331 · $0.4586
Ran-Donepezil · DIN 02381508 · $0.4586
Sandoz Donepezil · DIN 02328666 · $0.4586
Septa-Donepezil · DIN 02428482 · $0.4586
Teva-Donepezil · DIN 02340607 · $0.4586
Shortage status: resolved shortage (ended 2024-11-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02426846
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Donepezil · DIN 02475278 · 5mg · tablet
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Donepezil · DIN 02475278
Manufacturer: Laboratoire Riva Inc.; listing date 2021-08-31
Health Canada: Marketed since 2018-05-16 · brand DONEPEZIL · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE 5 MG · company Laboratoire riva inc. · schedule Prescription
Donepezil: Formulary list price $0.4586/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4586 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96563 · Verify on the e-Formulary ↗ (DIN 02475278)
Source record
DIN 02475278: Donepezil
Raw flags: sec12=Y, sec3=Y
Item: 120400017; group id 193; item number 0354; lccId 00026; manufacturer id RIA
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4586; ministry $0.4586
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02475278
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96563
Interchangeable products
AG-Donepezil · DIN 02432684 · $0.4586
Ach-Donepezil · DIN 02402645 · $0.4586
Apo-Donepezil · DIN 02362260 · $0.4586
Aricept · DIN 02232043 · $0.4586
Auro-Donepezil · DIN 02400561 · $0.4586
Bio-Donepezil · DIN 02412853 · $0.4586
Co Donepezil · DIN 02397595 · $0.4586
Donepezil · DIN 02420597 · $0.4586
Donepezil · DIN 02426846 · $0.4586
Jamp-Donepezil · DIN 02404419 · $0.4586
Jamp-Donepezil Tablets · DIN 02416948 · $0.4586
M-Donepezil · DIN 02467453 · $0.4586
Mar-Donepezil · DIN 02402092 · $0.4586
Mint-Donepezil · DIN 02408600 · $0.4586
NRA-Donepezil · DIN 02535386 · $0.4586
PMS-Donepezil · DIN 02322331 · $0.4586
Ran-Donepezil · DIN 02381508 · $0.4586
Sandoz Donepezil · DIN 02328666 · $0.4586
Septa-Donepezil · DIN 02428482 · $0.4586
Teva-Donepezil · DIN 02340607 · $0.4586
Shortage status: active shortage (reported 2024-01-12, last updated 2024-01-15) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02475278
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Donepezil Tablets · DIN 02416948 · 5mg · tablet
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Donepezil Tablets · DIN 02416948
Manufacturer: Jamp Pharma Corporation; listing date 2014-12-18
Health Canada: Marketed since 2014-09-26 · brand JAMP-DONEPEZIL TABLETS · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE 5 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Donepezil Tablets: Formulary list price $0.4586/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4586 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90157 · Verify on the e-Formulary ↗ (DIN 02416948)
Source record
DIN 02416948: Jamp-Donepezil Tablets
Raw flags: sec12=Y, sec3=Y
Item: 120400017; group id 193; item number 0354; lccId 00026; manufacturer id JPC
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4586; ministry $0.4586
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02416948
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90157
Interchangeable products
AG-Donepezil · DIN 02432684 · $0.4586
Ach-Donepezil · DIN 02402645 · $0.4586
Apo-Donepezil · DIN 02362260 · $0.4586
Aricept · DIN 02232043 · $0.4586
Auro-Donepezil · DIN 02400561 · $0.4586
Bio-Donepezil · DIN 02412853 · $0.4586
Co Donepezil · DIN 02397595 · $0.4586
Donepezil · DIN 02420597 · $0.4586
Donepezil · DIN 02426846 · $0.4586
Donepezil · DIN 02475278 · $0.4586
Jamp-Donepezil · DIN 02404419 · $0.4586
M-Donepezil · DIN 02467453 · $0.4586
Mar-Donepezil · DIN 02402092 · $0.4586
Mint-Donepezil · DIN 02408600 · $0.4586
NRA-Donepezil · DIN 02535386 · $0.4586
PMS-Donepezil · DIN 02322331 · $0.4586
Ran-Donepezil · DIN 02381508 · $0.4586
Sandoz Donepezil · DIN 02328666 · $0.4586
Septa-Donepezil · DIN 02428482 · $0.4586
Teva-Donepezil · DIN 02340607 · $0.4586
Shortage status: resolved shortage (ended 2026-09-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02416948
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Donepezil · DIN 02467453 · 5mg · tablet
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
M-Donepezil · DIN 02467453
Manufacturer: Mantra Pharma Inc.; listing date 2021-10-29
Health Canada: Marketed since 2017-12-14 · brand M-DONEPEZIL · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE 5 MG · company Mantra pharma inc · schedule Prescription
M-Donepezil: Formulary list price $0.4586/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4586 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95583 · Verify on the e-Formulary ↗ (DIN 02467453)
Source record
DIN 02467453: M-Donepezil
Raw flags: sec12=Y, sec3=Y
Item: 120400017; group id 193; item number 0354; lccId 00026; manufacturer id MAT
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4586; ministry $0.4586
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02467453
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95583
Interchangeable products
AG-Donepezil · DIN 02432684 · $0.4586
Ach-Donepezil · DIN 02402645 · $0.4586
Apo-Donepezil · DIN 02362260 · $0.4586
Aricept · DIN 02232043 · $0.4586
Auro-Donepezil · DIN 02400561 · $0.4586
Bio-Donepezil · DIN 02412853 · $0.4586
Co Donepezil · DIN 02397595 · $0.4586
Donepezil · DIN 02420597 · $0.4586
Donepezil · DIN 02426846 · $0.4586
Donepezil · DIN 02475278 · $0.4586
Jamp-Donepezil · DIN 02404419 · $0.4586
Jamp-Donepezil Tablets · DIN 02416948 · $0.4586
Mar-Donepezil · DIN 02402092 · $0.4586
Mint-Donepezil · DIN 02408600 · $0.4586
NRA-Donepezil · DIN 02535386 · $0.4586
PMS-Donepezil · DIN 02322331 · $0.4586
Ran-Donepezil · DIN 02381508 · $0.4586
Sandoz Donepezil · DIN 02328666 · $0.4586
Septa-Donepezil · DIN 02428482 · $0.4586
Teva-Donepezil · DIN 02340607 · $0.4586
Shortage status: resolved shortage (ended 2025-06-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02467453
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mar-Donepezil · DIN 02402092 · 5mg · tablet
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mar-Donepezil · DIN 02402092
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2014-02-27
Health Canada: Marketed since 2014-01-06 · brand MAR-DONEPEZIL · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE 5 MG · company Marcan pharmaceuticals inc · schedule Prescription
Mar-Donepezil: Formulary list price $0.4586/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4586 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88696 · Verify on the e-Formulary ↗ (DIN 02402092)
Source record
DIN 02402092: Mar-Donepezil
Raw flags: sec12=Y, sec3=Y
Item: 120400017; group id 193; item number 0354; lccId 00026; manufacturer id MAR
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4586; ministry $0.4586
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02402092
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88696
Interchangeable products
AG-Donepezil · DIN 02432684 · $0.4586
Ach-Donepezil · DIN 02402645 · $0.4586
Apo-Donepezil · DIN 02362260 · $0.4586
Aricept · DIN 02232043 · $0.4586
Auro-Donepezil · DIN 02400561 · $0.4586
Bio-Donepezil · DIN 02412853 · $0.4586
Co Donepezil · DIN 02397595 · $0.4586
Donepezil · DIN 02420597 · $0.4586
Donepezil · DIN 02426846 · $0.4586
Donepezil · DIN 02475278 · $0.4586
Jamp-Donepezil · DIN 02404419 · $0.4586
Jamp-Donepezil Tablets · DIN 02416948 · $0.4586
M-Donepezil · DIN 02467453 · $0.4586
Mint-Donepezil · DIN 02408600 · $0.4586
NRA-Donepezil · DIN 02535386 · $0.4586
PMS-Donepezil · DIN 02322331 · $0.4586
Ran-Donepezil · DIN 02381508 · $0.4586
Sandoz Donepezil · DIN 02328666 · $0.4586
Septa-Donepezil · DIN 02428482 · $0.4586
Teva-Donepezil · DIN 02340607 · $0.4586
Shortage status: discontinued (2017-03-13, reported by MARCAN PHARMACEUTICALS INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02402092
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Donepezil · DIN 02408600 · 5mg · tablet
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Donepezil · DIN 02408600
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2019-09-30
Health Canada: Marketed since 2019-06-11 · brand MINT-DONEPEZIL · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE 5 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Donepezil: Formulary list price $0.4586/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4586 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89334 · Verify on the e-Formulary ↗ (DIN 02408600)
Source record
DIN 02408600: Mint-Donepezil
Raw flags: sec12=Y, sec3=Y
Item: 120400017; group id 193; item number 0354; lccId 00026; manufacturer id MIN
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4586; ministry $0.4586
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02408600
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89334
Interchangeable products
AG-Donepezil · DIN 02432684 · $0.4586
Ach-Donepezil · DIN 02402645 · $0.4586
Apo-Donepezil · DIN 02362260 · $0.4586
Aricept · DIN 02232043 · $0.4586
Auro-Donepezil · DIN 02400561 · $0.4586
Bio-Donepezil · DIN 02412853 · $0.4586
Co Donepezil · DIN 02397595 · $0.4586
Donepezil · DIN 02420597 · $0.4586
Donepezil · DIN 02426846 · $0.4586
Donepezil · DIN 02475278 · $0.4586
Jamp-Donepezil · DIN 02404419 · $0.4586
Jamp-Donepezil Tablets · DIN 02416948 · $0.4586
M-Donepezil · DIN 02467453 · $0.4586
Mar-Donepezil · DIN 02402092 · $0.4586
NRA-Donepezil · DIN 02535386 · $0.4586
PMS-Donepezil · DIN 02322331 · $0.4586
Ran-Donepezil · DIN 02381508 · $0.4586
Sandoz Donepezil · DIN 02328666 · $0.4586
Septa-Donepezil · DIN 02428482 · $0.4586
Teva-Donepezil · DIN 02340607 · $0.4586
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02408600
Shortage record checked 2026-09-13T08:10:21.292534+00:00
NRA-Donepezil · DIN 02535386 · 5mg · tablet
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Donepezil · DIN 02535386
Manufacturer: Nora Pharma; listing date 2024-01-31
Health Canada: Marketed since 2023-10-16 · brand NRA-DONEPEZIL · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE 5 MG · company Nora pharma inc · schedule Prescription
NRA-Donepezil: Formulary list price $0.4586/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4586 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102424 · Verify on the e-Formulary ↗ (DIN 02535386)
Source record
DIN 02535386: NRA-Donepezil
Raw flags: sec12=Y, sec3=Y
Item: 120400017; group id 193; item number 0354; lccId 00026; manufacturer id NRA
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4586; ministry $0.4586
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02535386
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102424
Interchangeable products
AG-Donepezil · DIN 02432684 · $0.4586
Ach-Donepezil · DIN 02402645 · $0.4586
Apo-Donepezil · DIN 02362260 · $0.4586
Aricept · DIN 02232043 · $0.4586
Auro-Donepezil · DIN 02400561 · $0.4586
Bio-Donepezil · DIN 02412853 · $0.4586
Co Donepezil · DIN 02397595 · $0.4586
Donepezil · DIN 02420597 · $0.4586
Donepezil · DIN 02426846 · $0.4586
Donepezil · DIN 02475278 · $0.4586
Jamp-Donepezil · DIN 02404419 · $0.4586
Jamp-Donepezil Tablets · DIN 02416948 · $0.4586
M-Donepezil · DIN 02467453 · $0.4586
Mar-Donepezil · DIN 02402092 · $0.4586
Mint-Donepezil · DIN 02408600 · $0.4586
PMS-Donepezil · DIN 02322331 · $0.4586
Ran-Donepezil · DIN 02381508 · $0.4586
Sandoz Donepezil · DIN 02328666 · $0.4586
Septa-Donepezil · DIN 02428482 · $0.4586
Teva-Donepezil · DIN 02340607 · $0.4586
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02535386
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Donepezil · DIN 02322331 · 5mg · tablet
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Donepezil · DIN 02322331
Manufacturer: Pharmascience Inc.; listing date 2014-02-27
Health Canada: Marketed since 2013-12-27 · brand PMS-DONEPEZIL · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE (DONEPEZIL HYDROCHLORIDE MONOHYDRATE) 5 MG · company Pharmascience inc · schedule Prescription
PMS-Donepezil: Formulary list price $0.4586/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4586 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80779 · Verify on the e-Formulary ↗ (DIN 02322331)
Source record
DIN 02322331: PMS-Donepezil
Raw flags: sec12=Y, sec3=Y
Item: 120400017; group id 193; item number 0354; lccId 00026; manufacturer id PMS
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4586; ministry $0.4586
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02322331
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80779
Interchangeable products
AG-Donepezil · DIN 02432684 · $0.4586
Ach-Donepezil · DIN 02402645 · $0.4586
Apo-Donepezil · DIN 02362260 · $0.4586
Aricept · DIN 02232043 · $0.4586
Auro-Donepezil · DIN 02400561 · $0.4586
Bio-Donepezil · DIN 02412853 · $0.4586
Co Donepezil · DIN 02397595 · $0.4586
Donepezil · DIN 02420597 · $0.4586
Donepezil · DIN 02426846 · $0.4586
Donepezil · DIN 02475278 · $0.4586
Jamp-Donepezil · DIN 02404419 · $0.4586
Jamp-Donepezil Tablets · DIN 02416948 · $0.4586
M-Donepezil · DIN 02467453 · $0.4586
Mar-Donepezil · DIN 02402092 · $0.4586
Mint-Donepezil · DIN 02408600 · $0.4586
NRA-Donepezil · DIN 02535386 · $0.4586
Ran-Donepezil · DIN 02381508 · $0.4586
Sandoz Donepezil · DIN 02328666 · $0.4586
Septa-Donepezil · DIN 02428482 · $0.4586
Teva-Donepezil · DIN 02340607 · $0.4586
Shortage status: resolved shortage (ended 2026-08-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02322331
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ran-Donepezil · DIN 02381508 · 5mg · tablet
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ran-Donepezil · DIN 02381508
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2014-02-27
Health Canada: Marketed since 2020-03-10 · brand TARO-DONEPEZIL · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE 5 MG · company Sun pharma canada inc · schedule Prescription
Ran-Donepezil: Formulary list price $0.4586/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4586 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86735 · Verify on the e-Formulary ↗ (DIN 02381508)
Source record
DIN 02381508: Ran-Donepezil
Raw flags: sec12=Y, sec3=Y
Item: 120400017; group id 193; item number 0354; lccId 00026; manufacturer id RAN
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4586; ministry $0.4586
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02381508
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86735
Interchangeable products
AG-Donepezil · DIN 02432684 · $0.4586
Ach-Donepezil · DIN 02402645 · $0.4586
Apo-Donepezil · DIN 02362260 · $0.4586
Aricept · DIN 02232043 · $0.4586
Auro-Donepezil · DIN 02400561 · $0.4586
Bio-Donepezil · DIN 02412853 · $0.4586
Co Donepezil · DIN 02397595 · $0.4586
Donepezil · DIN 02420597 · $0.4586
Donepezil · DIN 02426846 · $0.4586
Donepezil · DIN 02475278 · $0.4586
Jamp-Donepezil · DIN 02404419 · $0.4586
Jamp-Donepezil Tablets · DIN 02416948 · $0.4586
M-Donepezil · DIN 02467453 · $0.4586
Mar-Donepezil · DIN 02402092 · $0.4586
Mint-Donepezil · DIN 02408600 · $0.4586
NRA-Donepezil · DIN 02535386 · $0.4586
PMS-Donepezil · DIN 02322331 · $0.4586
Sandoz Donepezil · DIN 02328666 · $0.4586
Septa-Donepezil · DIN 02428482 · $0.4586
Teva-Donepezil · DIN 02340607 · $0.4586
Shortage status: resolved shortage (ended 2025-04-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02381508
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Donepezil · DIN 02328666 · 5mg · tablet
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Donepezil · DIN 02328666
Manufacturer: Sandoz Canada Inc.; listing date 2014-03-27
Health Canada: Marketed since 2013-12-27 · brand SANDOZ DONEPEZIL · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE 5 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Donepezil: Formulary list price $0.4586/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4586 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81417 · Verify on the e-Formulary ↗ (DIN 02328666)
Source record
DIN 02328666: Sandoz Donepezil
Raw flags: sec12=Y, sec3=Y
Item: 120400017; group id 193; item number 0354; lccId 00026; manufacturer id SDZ
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4586; ministry $0.4586
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02328666
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81417
Interchangeable products
AG-Donepezil · DIN 02432684 · $0.4586
Ach-Donepezil · DIN 02402645 · $0.4586
Apo-Donepezil · DIN 02362260 · $0.4586
Aricept · DIN 02232043 · $0.4586
Auro-Donepezil · DIN 02400561 · $0.4586
Bio-Donepezil · DIN 02412853 · $0.4586
Co Donepezil · DIN 02397595 · $0.4586
Donepezil · DIN 02420597 · $0.4586
Donepezil · DIN 02426846 · $0.4586
Donepezil · DIN 02475278 · $0.4586
Jamp-Donepezil · DIN 02404419 · $0.4586
Jamp-Donepezil Tablets · DIN 02416948 · $0.4586
M-Donepezil · DIN 02467453 · $0.4586
Mar-Donepezil · DIN 02402092 · $0.4586
Mint-Donepezil · DIN 02408600 · $0.4586
NRA-Donepezil · DIN 02535386 · $0.4586
PMS-Donepezil · DIN 02322331 · $0.4586
Ran-Donepezil · DIN 02381508 · $0.4586
Septa-Donepezil · DIN 02428482 · $0.4586
Teva-Donepezil · DIN 02340607 · $0.4586
Shortage status: resolved shortage (ended 2020-04-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02328666
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Donepezil · DIN 02340607 · 5mg · tablet
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Donepezil · DIN 02340607
Manufacturer: Teva Canada Limited; listing date 2014-02-27
Health Canada: Marketed since 2013-12-27 · brand TEVA-DONEPEZIL · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE 5 MG · company Teva canada limited · schedule Prescription
Teva-Donepezil: Formulary list price $0.4586/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4586 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82618 · Verify on the e-Formulary ↗ (DIN 02340607)
Source record
DIN 02340607: Teva-Donepezil
Raw flags: sec12=Y, sec3=Y
Item: 120400017; group id 193; item number 0354; lccId 00026; manufacturer id TEV
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4586; ministry $0.4586
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02340607
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82618
Interchangeable products
AG-Donepezil · DIN 02432684 · $0.4586
Ach-Donepezil · DIN 02402645 · $0.4586
Apo-Donepezil · DIN 02362260 · $0.4586
Aricept · DIN 02232043 · $0.4586
Auro-Donepezil · DIN 02400561 · $0.4586
Bio-Donepezil · DIN 02412853 · $0.4586
Co Donepezil · DIN 02397595 · $0.4586
Donepezil · DIN 02420597 · $0.4586
Donepezil · DIN 02426846 · $0.4586
Donepezil · DIN 02475278 · $0.4586
Jamp-Donepezil · DIN 02404419 · $0.4586
Jamp-Donepezil Tablets · DIN 02416948 · $0.4586
M-Donepezil · DIN 02467453 · $0.4586
Mar-Donepezil · DIN 02402092 · $0.4586
Mint-Donepezil · DIN 02408600 · $0.4586
NRA-Donepezil · DIN 02535386 · $0.4586
PMS-Donepezil · DIN 02322331 · $0.4586
Ran-Donepezil · DIN 02381508 · $0.4586
Sandoz Donepezil · DIN 02328666 · $0.4586
Septa-Donepezil · DIN 02428482 · $0.4586
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02340607
Shortage record checked 2026-09-13T08:10:21.292534+00:00
AG-Donepezil · DIN 02432692 · 10mg · tablet
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
AG-Donepezil · DIN 02432692
Manufacturer: Angita Pharma Inc.; listing date 2021-09-30
Health Canada: Marketed since 2021-05-10 · brand AG-DONEPEZIL · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE 10 MG · company Angita pharma inc. · schedule Prescription
AG-Donepezil: Formulary list price $0.4586/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4586 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91712 · Verify on the e-Formulary ↗ (DIN 02432692)
Source record
DIN 02432692: AG-Donepezil
Raw flags: sec12=Y, sec3=Y
Item: 120400018; group id 193; item number 0355; lccId 00026; manufacturer id ANG
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4586; ministry $0.4586
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02432692
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91712
Interchangeable products
Ach-Donepezil · DIN 02402653 · $0.4586
Apo-Donepezil · DIN 02362279 · $0.4586
Aricept · DIN 02232044 · $0.4586
Auro-Donepezil · DIN 02400588 · $0.4586
Bio-Donepezil · DIN 02412861 · $0.4586
Co Donepezil · DIN 02397609 · $0.4586
Donepezil · DIN 02420600 · $0.4586
Donepezil · DIN 02426854 · $0.4586
Donepezil · DIN 02475286 · $0.4586
Jamp-Donepezil · DIN 02404427 · $0.4586
Jamp-Donepezil Tablets · DIN 02416956 · $0.4586
M-Donepezil · DIN 02467461 · $0.4586
Mar-Donepezil · DIN 02402106 · $0.4586
Mint-Donepezil · DIN 02408619 · $0.4586
NRA-Donepezil · DIN 02535394 · $0.4586
PMS-Donepezil · DIN 02322358 · $0.4586
Ran-Donepezil · DIN 02381516 · $0.4586
Sandoz Donepezil · DIN 02328682 · $0.4586
Septa-Donepezil · DIN 02428490 · $0.4586
Teva-Donepezil · DIN 02340615 · $0.4586
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02432692
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ach-Donepezil · DIN 02402653 · 10mg · tablet
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ach-Donepezil · DIN 02402653
Manufacturer: Accord Healthcare Inc.; listing date 2014-05-29
Health Canada: Marketed since 2023-08-04 · brand ACH-DONEPEZIL · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE 10 MG · company Accord healthcare inc · schedule Prescription
Ach-Donepezil: Formulary list price $0.4586/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4586 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88750 · Verify on the e-Formulary ↗ (DIN 02402653)
Source record
DIN 02402653: Ach-Donepezil
Raw flags: sec12=Y, sec3=Y
Item: 120400018; group id 193; item number 0355; lccId 00026; manufacturer id ACH
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4586; ministry $0.4586
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02402653
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88750
Interchangeable products
AG-Donepezil · DIN 02432692 · $0.4586
Apo-Donepezil · DIN 02362279 · $0.4586
Aricept · DIN 02232044 · $0.4586
Auro-Donepezil · DIN 02400588 · $0.4586
Bio-Donepezil · DIN 02412861 · $0.4586
Co Donepezil · DIN 02397609 · $0.4586
Donepezil · DIN 02420600 · $0.4586
Donepezil · DIN 02426854 · $0.4586
Donepezil · DIN 02475286 · $0.4586
Jamp-Donepezil · DIN 02404427 · $0.4586
Jamp-Donepezil Tablets · DIN 02416956 · $0.4586
M-Donepezil · DIN 02467461 · $0.4586
Mar-Donepezil · DIN 02402106 · $0.4586
Mint-Donepezil · DIN 02408619 · $0.4586
NRA-Donepezil · DIN 02535394 · $0.4586
PMS-Donepezil · DIN 02322358 · $0.4586
Ran-Donepezil · DIN 02381516 · $0.4586
Sandoz Donepezil · DIN 02328682 · $0.4586
Septa-Donepezil · DIN 02428490 · $0.4586
Teva-Donepezil · DIN 02340615 · $0.4586
Shortage status: active shortage (reported 2025-11-05, last updated 2025-12-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02402653
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Donepezil · DIN 02362279 · 10mg · tablet
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Donepezil · DIN 02362279
Manufacturer: Apotex Inc.; listing date 2014-02-27
Health Canada: Marketed since 2014-12-27 · brand APO-DONEPEZIL · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE (DONEPEZIL HYDROCHLORIDE MONOHYDRATE) 10 MG · company Apotex inc · schedule Prescription
Apo-Donepezil: Formulary list price $0.4586/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4586 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84729 · Verify on the e-Formulary ↗ (DIN 02362279)
Source record
DIN 02362279: Apo-Donepezil
Raw flags: sec12=Y, sec3=Y
Item: 120400018; group id 193; item number 0355; lccId 00026; manufacturer id APX
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4586; ministry $0.4586
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02362279
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84729
Interchangeable products
AG-Donepezil · DIN 02432692 · $0.4586
Ach-Donepezil · DIN 02402653 · $0.4586
Aricept · DIN 02232044 · $0.4586
Auro-Donepezil · DIN 02400588 · $0.4586
Bio-Donepezil · DIN 02412861 · $0.4586
Co Donepezil · DIN 02397609 · $0.4586
Donepezil · DIN 02420600 · $0.4586
Donepezil · DIN 02426854 · $0.4586
Donepezil · DIN 02475286 · $0.4586
Jamp-Donepezil · DIN 02404427 · $0.4586
Jamp-Donepezil Tablets · DIN 02416956 · $0.4586
M-Donepezil · DIN 02467461 · $0.4586
Mar-Donepezil · DIN 02402106 · $0.4586
Mint-Donepezil · DIN 02408619 · $0.4586
NRA-Donepezil · DIN 02535394 · $0.4586
PMS-Donepezil · DIN 02322358 · $0.4586
Ran-Donepezil · DIN 02381516 · $0.4586
Sandoz Donepezil · DIN 02328682 · $0.4586
Septa-Donepezil · DIN 02428490 · $0.4586
Teva-Donepezil · DIN 02340615 · $0.4586
Shortage status: active shortage (reported 2025-08-06, last updated 2025-09-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02362279
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Aricept · DIN 02232044 · 10mg · tablet
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Savings card: RxHelp ONE lists Aricept (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Aricept · DIN 02232044
Manufacturer: Pfizer Canada Inc.; listing date 1999-06-01
Health Canada: Marketed since 1997-08-20 · brand ARICEPT · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE 10 MG · company Pfizer canada ulc · schedule Prescription
Ministry pays: $0.4586 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=51492 · Verify on the e-Formulary ↗ (DIN 02232044)
Source record
DIN 02232044: Aricept
Raw flags: sec12=Y, sec3=Y
Item: 120400018; group id 193; item number 0355; lccId 00026; manufacturer id PFI
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $5.1856; ministry $0.4586
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02232044
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=51492
Interchangeable products
AG-Donepezil · DIN 02432692 · $0.4586
Ach-Donepezil · DIN 02402653 · $0.4586
Apo-Donepezil · DIN 02362279 · $0.4586
Auro-Donepezil · DIN 02400588 · $0.4586
Bio-Donepezil · DIN 02412861 · $0.4586
Co Donepezil · DIN 02397609 · $0.4586
Donepezil · DIN 02420600 · $0.4586
Donepezil · DIN 02426854 · $0.4586
Donepezil · DIN 02475286 · $0.4586
Jamp-Donepezil · DIN 02404427 · $0.4586
Jamp-Donepezil Tablets · DIN 02416956 · $0.4586
M-Donepezil · DIN 02467461 · $0.4586
Mar-Donepezil · DIN 02402106 · $0.4586
Mint-Donepezil · DIN 02408619 · $0.4586
NRA-Donepezil · DIN 02535394 · $0.4586
PMS-Donepezil · DIN 02322358 · $0.4586
Ran-Donepezil · DIN 02381516 · $0.4586
Sandoz Donepezil · DIN 02328682 · $0.4586
Septa-Donepezil · DIN 02428490 · $0.4586
Teva-Donepezil · DIN 02340615 · $0.4586
Shortage status: resolved shortage (ended 2026-07-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02232044
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Donepezil · DIN 02400588 · 10mg · tablet
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Donepezil · DIN 02400588
Manufacturer: Auro Pharma Inc.; listing date 2014-02-27
Health Canada: Marketed since 2013-12-27 · brand AURO-DONEPEZIL · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE 10 MG · company Auro pharma inc · schedule Prescription
Auro-Donepezil: Formulary list price $0.4586/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4586 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88537 · Verify on the e-Formulary ↗ (DIN 02400588)
Source record
DIN 02400588: Auro-Donepezil
Raw flags: sec12=Y, sec3=Y
Item: 120400018; group id 193; item number 0355; lccId 00026; manufacturer id AUR
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4586; ministry $0.4586
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02400588
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88537
Interchangeable products
AG-Donepezil · DIN 02432692 · $0.4586
Ach-Donepezil · DIN 02402653 · $0.4586
Apo-Donepezil · DIN 02362279 · $0.4586
Aricept · DIN 02232044 · $0.4586
Bio-Donepezil · DIN 02412861 · $0.4586
Co Donepezil · DIN 02397609 · $0.4586
Donepezil · DIN 02420600 · $0.4586
Donepezil · DIN 02426854 · $0.4586
Donepezil · DIN 02475286 · $0.4586
Jamp-Donepezil · DIN 02404427 · $0.4586
Jamp-Donepezil Tablets · DIN 02416956 · $0.4586
M-Donepezil · DIN 02467461 · $0.4586
Mar-Donepezil · DIN 02402106 · $0.4586
Mint-Donepezil · DIN 02408619 · $0.4586
NRA-Donepezil · DIN 02535394 · $0.4586
PMS-Donepezil · DIN 02322358 · $0.4586
Ran-Donepezil · DIN 02381516 · $0.4586
Sandoz Donepezil · DIN 02328682 · $0.4586
Septa-Donepezil · DIN 02428490 · $0.4586
Teva-Donepezil · DIN 02340615 · $0.4586
Shortage status: resolved shortage (ended 2023-08-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02400588
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Bio-Donepezil · DIN 02412861 · 10mg · tablet
Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-02
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Bio-Donepezil · DIN 02412861
Manufacturer: Biomed Pharma; listing date 2016-04-29
Health Canada: Marketed since 2013-12-27 · brand BIO-DONEPEZIL · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE 10 MG · company Biomed pharma · schedule Prescription
Bio-Donepezil: Formulary list price $0.4586/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4586 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89757 · Verify on the e-Formulary ↗ (DIN 02412861)
Source record
DIN 02412861: Bio-Donepezil
Raw flags: sec12=Y, sec3=Y
Item: 120400018; group id 193; item number 0355; lccId 00026; manufacturer id BMP
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4586; ministry $0.4586
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02412861
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89757
Interchangeable products
AG-Donepezil · DIN 02432692 · $0.4586
Ach-Donepezil · DIN 02402653 · $0.4586
Apo-Donepezil · DIN 02362279 · $0.4586
Aricept · DIN 02232044 · $0.4586
Auro-Donepezil · DIN 02400588 · $0.4586
Co Donepezil · DIN 02397609 · $0.4586
Donepezil · DIN 02420600 · $0.4586
Donepezil · DIN 02426854 · $0.4586
Donepezil · DIN 02475286 · $0.4586
Jamp-Donepezil · DIN 02404427 · $0.4586
Jamp-Donepezil Tablets · DIN 02416956 · $0.4586
M-Donepezil · DIN 02467461 · $0.4586
Mar-Donepezil · DIN 02402106 · $0.4586
Mint-Donepezil · DIN 02408619 · $0.4586
NRA-Donepezil · DIN 02535394 · $0.4586
PMS-Donepezil · DIN 02322358 · $0.4586
Ran-Donepezil · DIN 02381516 · $0.4586
Sandoz Donepezil · DIN 02328682 · $0.4586
Septa-Donepezil · DIN 02428490 · $0.4586
Teva-Donepezil · DIN 02340615 · $0.4586
Shortage status: resolved shortage (ended 2021-10-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02412861
Shortage record checked 2026-09-13T08:10:21.292534+00:00